

**Appendix 2 (as supplied by authors): Compliance to Guideline Endpoints – Site Level Analysis**

	Pre-implementation		Post-implementation		Between-group Comparisons - P Value <sup>y</sup>		
<b>Guideline</b>	<b>Compliance of Experimental Group, % (SD)</b>	<b>Compliance of Control Group, % (SD)</b>	<b>Compliance of Experimental Group, % (SD)</b>	<b>Compliance of Control Group, % (SD)</b>	(1)	(2)	(3)
Primary Outcome							
Endoscopic hemostasis followed by high-dose IV PPI	13 (18)	6 (10)	7 (10)	5 (12)	.188	.623	.472
<b>Secondary Outcomes</b>							
Injection and/or thermal coagulation without clips and bolus IV PPI followed by infusion for 72 hours for high-risk ulcers	8 (11)	4(9)	4 (9)	5 (12)	.122	.210	.120
Injection and/or thermal coagulation stigmata with clips and bolus IV PPI followed by 8 mg/hr infusion for 72 hours & no oral PPI. If pre-endoscopy infusion, absence of bolus IV PPI post-endoscopy ignored.	72 (27)	61 (25)	57 (31)	67 (30)	.033	.097	.094
Injection and/or thermal coagulation with clips and Pre-endoscopy bolus of PPI plus 80-mg bolus IV PPI followed by 8 mg/hr infusion for 72 hours post-endoscopic therapy & no oral PPI.	1 (4)	1(5)	1 (3)	1 (4)	.899	.913	.819
Injection and/or thermal coagulation upon endoscopy for high-risk ulcers with clips alone	82 (22)	74 (25)	74 (30)	77 (31)	.193	.346	.368
Injection and/or thermal coagulation without clips for high-risk ulcers alone	46 (30)	49 (35)	54 (32)	54 (37)	.713	.817	.868
80-mg IV bolus followed by 8 mg/hr PPI infusion for 72 hours post-endoscopic therapy & no oral PPI.	15 (19)	9 (13)	10 (12)	10 (20)	.305	.660	.529
80-mg bolus IV PPI followed by 8 mg/hr infusion for 72 hours post-endoscopic therapy & no oral PPI. If pre-endoscopy infusion, absence of bolus IV PPI post-endoscopy ignored.	83 (16)	82 (16)	83 (19)	88 (14)	.299	.277	.329
Pre-endoscopy bolus of PPI plus 80-mg bolus IV PPI followed by 8 mg/hr infusion for 72 hours post-endoscopic therapy & no oral PPI.	1 (3)	1 (4)	1 (5)	4 (13)	.460	.347	.272

Early endoscopy (in the first 24 hours) with risk classification by clinical/endoscopic criteria	62 (18)	65 (13)	58 (24)	66 (16)	.417	.208	.113
No hemostasis for low risk lesion	86 (25)	94 (10)	93 (12)	88 (17)	.050	.138	.110
Endoscopic Hemostasis for adherent clot	89 (28)	87 (29)	76 (31)	81 (37)	.131	.268	.781
Endoscopic Hemostasis for other active bleeding or visible vessel	87 (16)	83 (21)	94 (9)	86 (19)	.619	.115	.107

γ (1) Unpaired t-test on differences, (2) Analysis of covariance adjusting for baseline (3) Analysis of covariance adjusting for baseline, bed size ( $\leq 400$  vs  $>400$ ), Ontario (yes/no) and interaction of bed size and Ontario

SD= Standard deviation